Podiatrist, Foot & Ankle Surgery · El Paso, TX
NPI
1336326255
Since 2008
Specialty
Podiatrist, Foot & Ankle Surgery
Code 213ES0103X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
1397 George Dieter Dr Ste A
El Paso, TX, 79936
Phone (915) 503-2020
Groups this clinician bills Medicare through
Medicare paid, 2024
$211K
2,167 services
Medicare patients, 2024
307
Average age 74
Drug cost, 2024
$129K
1,481 prescriptions
Company payments, 2025
$4,165
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sean M O'Meara was code 99213 (office e&m - established), 594 times for 242 patients. In total Sean M O'Meara billed 2,167 services in 58 codes, and Medicare paid $211K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-02-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 594 | 242 | $62.70 | $37K |
| 73630 X-ray - Lower Extremity | Office | 342 | 177 | $23.29 | $7,964 |
| 11721 Nail Procedure | Office | 266 | 100 | $30.29 | $8,057 |
| J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 144 | 38 | $5.44 | $784 |
| 99203 Office E&M - New | Office | 88 | 88 | $67.56 | $5,945 |
| 93922 Duplex Scan - Extremity Arteries | Office | 73 | 59 | $57.19 | $4,175 |
| 95923 Electrical Nerve Conductivity | Office | 73 | 59 | $79.99 | $5,840 |
| 76882 Ultrasound - Nonspecific | Office | 63 | 60 | $41.96 | $2,643 |
| 73610 X-ray - Lower Extremity | Office | 62 | 35 | $26.55 | $1,646 |
| 11042 Debridement | Office | 59 | 12 | $97.67 | $5,763 |
| 20605 Joint Injection | Office | 38 | 24 | $41.97 | $1,595 |
| 11056 Removal or Shaving of Skin Growth | Office | 18 | 12 | $53.17 | $957 |
| 99214 Office E&M - Established | Office | 11 | 11 | $95.04 | $1,045 |
By year: 2022 $139K for 2,542 services; 2023 $131K for 2,592 services; 2024 $211K for 2,167 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sean M O'Meara prescribed most often to Medicare patients was Methylprednisolone, with 186 prescriptions and refills. In total Sean M O'Meara wrote 1,481 Medicare prescriptions that cost $129K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methylprednisolone Generic | 186 | 186 | 169 | $1,474 |
| Meloxicam Generic | 181 | 201 | 144 | $520 |
| Gabapentin Generic | 118 | 196 | 66 | $1,230 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 94 | 94 | 53 | $683 |
| Clobetasol Emollient Clobetasol Propionate/Emoll | 73 | 73 | 52 | $40K |
| Cephalexin Generic | 71 | 71 | 49 | $465 |
| Ciclopirox Generic | 69 | 73 | 31 | $2,865 |
| Tramadol Hcl Generic | 64 | 64 | 29 | $207 |
| Clobetasol Propionate Generic | 61 | 61 | 36 | $11K |
| Mometasone Furoate Generic | 59 | 59 | 39 | $4,921 |
| Promethazine Hcl Generic | 57 | 57 | 52 | $203 |
| Celecoxib Generic | 55 | 65 | 37 | $549 |
| Desonide Generic | 54 | 54 | 45 | $26K |
| Ibuprofen Generic | 48 | 57 | 29 | $496 |
| Terbinafine Hcl Generic | 43 | 90 | 33 | $926 |
Brand drugs: 43 claims; generic drugs: 1,438 claims; opioid claims: 176.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sean M O'Meara $4,165 ($4,165 in general payments such as food, travel and fees) from 9 companies. The largest payer was Treace Medical Concepts, Inc. with $2,434.
| Company | Payments | Amount |
|---|---|---|
| Treace Medical Concepts, Inc. TMCI | 97 | $2,434 |
| Stryker Corporation SYK | 8 | $1,422 |
| Averitas Pharma Inc. | 2 | $149 |
| Paratek Pharmaceuticals, Inc. | 4 | $66.61 |
| Organogenesis Inc. ORGO | 1 | $23.72 |
| Smith+Nephew, Inc. SNN | 1 | $19.34 |
| Solventum Corporation SOLV | 1 | $18.62 |
| Fusion Orthopedics USA, LLC | 1 | $16.29 |
| Hartmann USA, Inc. | 1 | $15.97 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.